Skip to content
Insider tapeFilings through Fri, Oct 9
Watchlist
ALMS

ALUMIS (ALMS) stock: insider trades, news & valuation

Health Care · Strong buying
Close · Oct 9, 2026 $7.16 +2.7% on the day +58.1% over 12 months 52-week range $4.44 – $30.30

Share price and insider trades

ALMS closeInsider buyInsider sale
010203040NovDecJan 2026FebMarAprMayJunJulAugSepOctEEarnings release filed 2025-11-13EEarnings release filed 2026-01-09EEarnings release filed 2026-03-19EEarnings release filed 2026-05-14EEarnings release filed 2026-08-13Sold $140,000 on 2026-07-06 · Sanam PangaliBought $295,683 on 2025-11-28 · Srinivas AkkarajuBought $370,823 on 2025-11-26 · Srinivas AkkarajuSold $394,311 on 2026-08-03 · David M Goldstein, John R. Schroer, Jorn Drappa, Mark Christopher Bradley, Roy C. Hardiman, Sanam PangaliBought $540,101 on 2025-12-04 · Srinivas AkkarajuBought $644,171 on 2025-12-01 · Srinivas AkkarajuBought $724,800 on 2025-12-02 · Srinivas AkkarajuBought $775,000 on 2025-12-03 · Srinivas AkkarajuBought $905,350 on 2025-11-20 · Srinivas AkkarajuSold $1,014,182 on 2026-09-08 · Srinivas AkkarajuBought $1,449,940 on 2025-11-13 · Srinivas AkkarajuBought $1,598,774 on 2025-11-21 · Foresite Labs Affiliates 2021, Llc, Foresite Labs Fund I, L.P., James B. TananbaumBought $1,833,760 on 2025-12-05 · Srinivas AkkarajuBought $2,800,680 on 2025-11-18 · Foresite Capital Management Vi Llc, Foresite Labs Affiliates 2021, Llc, James B. Tananbaum, Srinivas AkkarajuBought $3,360,536 on 2025-11-17 · Foresite Capital Management Vi Llc, Foresite Labs Affiliates 2021, Llc, James B. Tananbaum, Srinivas AkkarajuBought $4,652,824 on 2025-11-19 · Foresite Capital Management Vi Llc, Foresite Labs Affiliates 2021, Llc, James B. Tananbaum, Srinivas AkkarajuBought $4,916,364 on 2026-09-04 · Srinivas AkkarajuBought $5,810,156 on 2026-09-08 · Srinivas AkkarajuBought $9,999,995 on 2026-01-09 · Srinivas AkkarajuBought $20,999,964 on 2026-01-08 · Foresite Labs Fund I, L.P., Foresite Labs, Llc, James B. Tananbaum
Bought, 12 months$61.7M
Sold, 12 months$1.5M
Insiders buying6
Insiders selling7

ALUMIS insider trading at a glance (Oct 9, 2026): in the past 12 months, 6 insiders bought $61.7M and 7 sold $1.5M of ALMS stock on the open market, including a cluster buy that began Jan 8, 2026.

ALMS insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q4 2025: $20.0M bought (29 trades)$20.0MQ4 2025Q1 2026: $31.0M bought (7 trades)$31.0MQ1 2026Q2 2026Q3 2026: $10.7M bought (4 trades)$10.7MQ3 2026: $1.5M sold (9 trades)Q3 2026Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0—0
Q3 2026$10.7M4$1.5M9
Q2 2026—0—0
Q1 2026$31.0M7—0
Q4 2025$20.0M29—0

Valuation, profit and volume

Pick score 51/100
P/E (trailing)n/aSector median 24.7
Market value$927MBiotechnology
Profit margin0.0%Revenue growth -37.7%
Volume vs. 50-day0.9×Last 5 sessions
Insiders' paper profit−$20.0MOn all tracked purchases -32.5%

Summary

Over the past 12 months, 6 ALUMIS INC. insiders reported open-market purchases totaling $61.7M, while 7 insiders reported sales totaling $1.5M. The most recent cluster buy began on Jan 8, 2026, when 4 insiders bought a combined $31.0M. Among insiders with enough purchase history to measure, Srinivas Akkaraju (Director) has the highest Insider Score at 100. 0 of 9 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

ALMS earnings: how the stock reacted

Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.

Does it matter? →
Release15 days beforeInsiders, 30 days beforeReaction (2 days)Next 30 days
Aug 13, 2026 -5.5% Sold $394K -0.9%S&P +0.5% -63.7%
May 14, 2026 +3.5% None -8.0%S&P -0.4% +5.6%
Mar 19, 2026 -9.7% None -1.4%S&P -1.7% -0.3%
Jan 9, 2026 +59.5% Bought $21.0M (3) +16.0%S&P +0.8% +21.5%
Nov 13, 2025 +8.9% None +5.3%S&P -1.7% +108.2%
Aug 13, 2025 +10.4% None -1.6%S&P +0.4% -0.5%
May 14, 2025 +8.3% None +20.0%S&P +0.6% -41.3%
Mar 19, 2025 -1.3% None -20.3%S&P +0.8% +40.1%

Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.

ALMS stock news and SEC filings

Recent 8-K filings and headlines. Tone is scored from the headline wording; “Policy” marks regulatory, trade or government topics.

Insider transactions

Open-market purchases and sales.

Filed Insider Type Shares Price Value Since Score
Sep 9SEC Srinivas AkkarajuDirector Buy 273,2914,937,026 held (+6%) $10.63 $2.9M -32.6% 100
Sep 9SEC Srinivas AkkarajuDirector Buy 273,2902,298,783 held (+13%) $10.63 $2.9M -32.6% 100
Sep 9SEC Srinivas AkkarajuDirector Buy 220,0704,711,801 held (+5%) $11.17 $2.5M -35.9% 100
Sep 9SEC Srinivas AkkarajuDirector Buy 220,0702,073,558 held (+12%) $11.17 $2.5M -35.9% 100
Sep 9SEC Srinivas AkkarajuDirector Sell 48,0664,663,735 held (−1%) $10.55 $507K -32.1% 100
Sep 9SEC Srinivas AkkarajuDirector Sell 48,0652,025,493 held (−2%) $10.55 $507K -32.1% 100
Aug 5SEC John R. SchroerCFO Sell 3,28224,718 held (−12%) $26.37 $87K -72.8% —
Aug 5SEC Roy C. HardimanChief Business & Strategy Ofcr Sell 2,692207,746 held (−1%) $26.37 $71K -72.8% —
Aug 5SEC David M GoldsteinChief Scientific Officer Sell 2,59630,970 held (−8%) $26.37 $68K -72.8% —
Aug 5SEC Mark Christopher BradleyChief Development Officer Sell 2,57248,533 held (−5%) $26.37 $68K -72.8% —
Aug 5SEC Jorn DrappaChief Medical Officer Sell 2,44756,892 held (−4%) $26.37 $65K -72.8% —
Aug 5SEC Sanam PangaliGeneral Counsel Sell 1,3649,747 held (−12%) $26.37 $36K -72.8% —
Jul 8SEC Sanam PangaliGeneral Counsel Sell 5,00011,111 held (−31%) $28.00 $140K -74.4% —
Jan 13SEC Srinivas AkkarajuDirector Buy 588,2351,853,488 held (+46%) $17.00 $10.0M -57.9% 100
Jan 12SEC Foresite Labs Fund I, L.P.10% Owner Buy 294,1172,908,332 held (+11%) $17.00 $5.0M -57.9% 100
Jan 12SEC James B. TananbaumDirector Buy 294,1172,908,332 held (+11%) $17.00 $5.0M -57.9% 100
Jan 12SEC Foresite Labs, Llc10% Owner Buy 294,1172,908,332 held (+11%) $17.00 $5.0M -57.9% —
Jan 12SEC Foresite Labs Fund I, L.P.10% Owner Buy 117,6475,702,536 held (+2%) $17.00 $2.0M -57.9% 100
Jan 12SEC James B. TananbaumDirector Buy 117,6475,702,536 held (+2%) $17.00 $2.0M -57.9% 100
Jan 12SEC Foresite Labs, Llc10% Owner Buy 117,6475,702,536 held (+2%) $17.00 $2.0M -57.9% —
Dec 9SEC Srinivas AkkarajuDirector Buy 70,0281,213,873 held (+6%) $10.01 $701K -28.5% 100
Dec 9SEC Srinivas AkkarajuDirector Buy 64,9691,143,845 held (+6%) $8.95 $581K -20.0% 100
Dec 9SEC Srinivas AkkarajuDirector Buy 51,3801,265,253 held (+4%) $10.73 $551K -33.3% 100
Dec 4SEC Srinivas AkkarajuDirector Buy 100,0001,012,849 held (+11%) $7.75 $775K -7.6% 100
Dec 4SEC Srinivas AkkarajuDirector Buy 96,000912,849 held (+12%) $7.55 $725K -5.2% 100
Dec 4SEC Srinivas AkkarajuDirector Buy 66,0271,078,876 held (+7%) $8.18 $540K -12.5% 100
Dec 1SEC Srinivas AkkarajuDirector Buy 86,350816,849 held (+12%) $7.46 $644K -4.0% 100
Dec 1SEC Srinivas AkkarajuDirector Buy 48,537691,797 held (+8%) $7.64 $371K -6.3% 100
Dec 1SEC Srinivas AkkarajuDirector Buy 38,702730,499 held (+6%) $7.64 $296K -6.3% 100
Nov 25SEC James B. TananbaumDirector Buy 72,2122,614,215 held (+3%) $7.38 $533K -3.0% 100
Nov 25SEC Foresite Labs Affiliates 2021, Llc10% Owner Buy 72,2122,614,215 held (+3%) $7.38 $533K -3.0% 100
Nov 25SEC Foresite Labs Fund I, L.P.10% Owner Buy 72,2122,614,215 held (+3%) $7.38 $533K -3.0% 100
Nov 24SEC Srinivas AkkarajuDirector Buy 125,743643,260 held (+24%) $7.20 $905K -0.6% 100
Nov 19SEC Foresite Capital Management Vi Llc10% Owner Buy 190,5002,542,003 held (+8%) $6.56 $1.2M +9.1% —
Nov 19SEC James B. TananbaumDirector Buy 190,5002,542,003 held (+8%) $6.56 $1.2M +9.1% 100
Nov 19SEC Foresite Labs Affiliates 2021, Llc10% Owner Buy 190,5002,542,003 held (+8%) $6.56 $1.2M +9.1% 100
Nov 19SEC Srinivas AkkarajuDirector Buy 137,772517,517 held (+36%) $6.56 $904K +9.1% 100
Nov 19SEC Foresite Capital Management Vi Llc10% Owner Buy 150,0002,234,129 held (+7%) $5.59 $838K +28.1% —
Nov 19SEC James B. TananbaumDirector Buy 150,0002,234,129 held (+7%) $5.59 $838K +28.1% 100
Nov 19SEC Foresite Labs Affiliates 2021, Llc10% Owner Buy 150,0002,234,129 held (+7%) $5.59 $838K +28.1% 100
Nov 19SEC Foresite Capital Management Vi Llc10% Owner Buy 117,3742,351,503 held (+5%) $6.19 $727K +15.7% —
Nov 19SEC James B. TananbaumDirector Buy 117,3742,351,503 held (+5%) $6.19 $727K +15.7% 100
Nov 19SEC Foresite Labs Affiliates 2021, Llc10% Owner Buy 117,3742,351,503 held (+5%) $6.19 $727K +15.7% 100
Nov 19SEC Srinivas AkkarajuDirector Buy 102,652379,745 held (+37%) $6.05 $621K +18.3% 100
Nov 19SEC Foresite Capital Management Vi Llc10% Owner Buy 50,0002,084,129 held (+2%) $5.60 $280K +27.9% —
Nov 19SEC James B. TananbaumDirector Buy 50,0002,084,129 held (+2%) $5.60 $280K +27.9% 100
Nov 19SEC Foresite Labs Affiliates 2021, Llc10% Owner Buy 50,0002,084,129 held (+2%) $5.60 $280K +27.9% 100
Nov 19SEC Srinivas AkkarajuDirector Buy 914277,093 held (+0%) $5.51 $5K +29.9% 100
Nov 17SEC Srinivas AkkarajuDirector Buy 276,179new position $5.25 $1.4M +36.4% 100

Insiders at ALUMIS INC.

InsiderBoughtSoldLast filingScore
Srinivas AkkarajuDirector $29.8M $1.0M Sep 9, 2026 100
James B. TananbaumDirector $10.6M — Jan 12, 2026 100
Foresite Labs Fund I, L.P.10% Owner $7.5M — Jan 12, 2026 100
Foresite Labs, Llc10% Owner $7.0M — Jan 12, 2026 —
Foresite Labs Affiliates 2021, Llc10% Owner $3.6M — Nov 25, 2025 100
Foresite Capital Management Vi Llc10% Owner $3.1M — Nov 19, 2025 —
Sanam PangaliGeneral Counsel — $176K Aug 5, 2026 —
John R. SchroerCFO — $87K Aug 5, 2026 —
Roy C. HardimanChief Business & Strategy Ofcr — $71K Aug 5, 2026 —
David M GoldsteinChief Scientific Officer — $68K Aug 5, 2026 —
Mark Christopher BradleyChief Development Officer — $68K Aug 5, 2026 —
Jorn DrappaChief Medical Officer — $65K Aug 5, 2026 —

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • SLBTSL Science Holding Ltd$10329.90B bought
  • KODKodiak Sciences Inc.$157M bought
  • ADRXADARx Pharmaceuticals, Inc.$87.7M bought
  • ATTOAttovia Therapeutics, Inc.$72.9M bought
  • MPLTMapLight Therapeutics, Inc.$65.5M bought
  • AVRAnteris Technologies Global Corp.$40.4M bought

ALMS stock: common questions

Are ALUMIS INC. insiders buying ALMS stock?

In the past 12 months, 6 insiders reported open-market purchases of ALMS worth $61.7M. The latest was Director Srinivas Akkaraju bought $2.9M of ALMS at $10.63.

Are ALUMIS INC. insiders selling ALMS stock?

7 insiders reported sales worth $1.5M over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is ALMS's 52-week range?

Over the past year ALMS has traded between $4.44 and $30.30. It last closed at $7.16 on Oct 9, 2026.